Since 2018, SAHPRA has maintained unwavering focus on patient safety through evidence-based regulatory mechanisms across all product categories. Recent data indicates that the authority achieved 95 percent completion rates for pre-market registration assessments and 92 percent adherence to quality and safety standards enforcement protocols. Post-market surveillance and monitoring operations reached 88 percent effectiveness, enabling rapid detection and response to emerging adverse events.
The authority’s statutory framework empowers rapid regulatory response when safety signals emerge, allowing SAHPRA to implement recalls, restrictions, or additional safety monitoring as circumstances require. This data-driven approach demonstrates how comprehensive regulatory architecture supports patient protection. Medical device regulation and complementary medicine oversight, while representing emerging regulatory domains, continue to strengthen SAHPRA’s capacity to protect healthcare consumers across diverse therapeutic areas.
Read the full article on GMJ Newsroom.
Was this article helpful?
